The safety Semaglutide and Tirzepatide are third and fourth-generation GLP-1 and GLP-1/GIP peptides that mimic the bodys natural gut hormones and act on specific brain areas that regulate hunger, reducing appetite and shifting body weight set point
A lot of people starting these medications are unfortunately flying blind with respect to what type of nutrition they should be prioritizing. Danone has built several tools to address this gap
A dietitian is a nutrition expert who can help you find those pieces and put them together
GLP-1a: Going beyond Traditional Use
Instead, they launched the most aggressive product imaginable, forced the FDA into a public response, and that response covers all GLP-1 APIs, including the injectables they were happily selling without scrutiny
The STEP-1 trial that established semaglutide for weight management capped doses at 2.4 mg weekly and produced 14.9% mean body-weight loss over 68 weeks (Wilding et al., 2021)